AbbVie's lutikizumab meets primary endpoint in Phase 3 HS study

Lutikizumab met the primary endpoint of HiSCR75 at Week 16 with a 31.4% response rate versus 23.4% for placebo. Eight ranked secondary endpoints were met, including significant improvements in skin pain and reduced flare occurrences. Pain reduction (NRS3) was achieved by 26.2% of patients at Week 8 compared to 15.0% on placebo. The study reported no new safety concerns, supporting continued development of the dual-variable-domain antagonist.

AbbVie signs ELAHERE reimbursement LoI with Pan-Canadian Pharmaceutical Alliance

AbbVie signed a Letter of Intent with the Pan-Canadian Pharmaceutical Alliance for ELAHERE reimbursement. ELAHERE is the first targeted monotherapy showing improved overall survival in platinum-resistant ovarian cancer. Approximately 3,000 individuals were diagnosed with ovarian cancer in Canada in 2026. The deal advances equitable access to treatment across provincial and territorial public drug plans.

AbbVie signs multi-year deal as McLaren F1 official pharma partner

AbbVie signs multi-year deal with McLaren Racing. Becomes official pharmaceutical partner of F1 team. Partnership centers on Race to Innovate campaign. Collaboration highlights shared focus on innovation.

AbbVie dual-target drug hits 30.2% remission in Crohn's phase 2

ABBV-466 achieved 30.2% endoscopic remission at Week 12 vs 21.3% for risankizumab. Remission rates rose to 40.5% for ABBV-466 at Week 24, widening the gap over monotherapies. Study included 300 patients, with 75% having failed at least one advanced therapy. Serious adverse event rates were comparable across all three treatment arms.

AbbVie to present seven oncology assets at ESMO 2026

AbbVie plans to present data on seven oncology assets at ESMO 2026. ABBV-706 showed 56% ORR and 12.4-month median OS in 2L+ small cell lung cancer. Presentations include Temab-A, ABBV-969, ABBV-1480, alveltamig, Emrelis, and Elahere. Data covers lung, colorectal, ovarian, prostate, and gastric cancers.

AbbVie SKYRIZI trial shows 35.8% endoscopic remission in Crohn's

35.8% of patients achieved endoscopic remission with subcutaneous SKYRIZI. 36.6% of patients with baseline ulcers achieved ulcer-free endoscopy. Therapy-naive patients showed higher efficacy with 45.1% remission rate. Data presented at the American College of Gastroenterology 2026 meeting.